Table 3.
Variation in expression levels of OR genes between schizophrenic patients and controls and between patient subgroups, when QKI expression levels are, or are not, accounted for
| Gene name | Analysis without QKI |
Analysis accounting for QKI levels |
||||
|---|---|---|---|---|---|---|
| Schizo. vs. Ctrl. (df = 1) |
Neuroleptic treatment (df = 2) |
Schizo. vs. Ctrl. |
Neuroleptic treatment |
|||
| SS | SS | SS−ΔQKI7kb | SSoverlap, % | SS−QKI | SSoverlap, % | |
| CDKN1B | 1.84* | 1.39 | 1.58 | 14 | 0.02 | 98 |
| SOX10 | 0.35 | 8.39* | 0.15 | 56 | 0.01 | 100 |
| MBP | 3.59 | 4.14 | 3.34 | 7 | 1.03 | 75 |
| TF | 5.81* | 18.12*** | 0.25 | 96 | 5.19 | 71 |
| PLP1 | 3.97* | 10.11** | 1.01 | 75 | 1.84 | 82 |
| MAG | 15.84** | 7.52 | 5.02 | 68 | 2.35 | 69 |
| S-MAG | 8.47** | 7.52** | 1.91 | 77 | 2.58 | 66 |
| L-MAG | 33.06*** | 7.03 | 19.23** | 42 | 3.97 | 44 |
| PC1 | 7.32 | 79.76** | 1.55 | 79 | 8.03 | 90 |
The variation in target gene expression explained by the disease status or the patient subgroup is listed for models excluding (left) or including (right) total QKI expression [schizophrenic (Schizo.) vs. control (Ctrl.)] or relative QKI-7kb (subgroup) levels. The reduction (or overlap) in variation is expressed as a percentage of the variation explained by models excluding QKI expression. Variation is estimated by sums of squares (SS). Asterisk (∗) indicates significant deviation in mRNA levels between patients and controls and between the three groups of patients (P < 0.05, P < 0.01, and P < 0.001, for one, two, and three asterisks, respectively).